Despite their antitumor efficacy, AIs are related to several long-term side effects like musculoskeletal disorders (i.e. arthralgia), secondary osteoporosis as a direct consequence of the hypo-estrogenic condition derived from the aromatase suppression (Tenti et al., 2020) and to anemia, which reduces muscle strength and induces a high inflammatory status (Natalucci et al., 2021). Here, CYP19A1 is linked to osteoporosis.